A

Adaptimmune Therapeutics plc

ADAP

1.27000
USD
-0.05
(-3.79%)
Market Open
Volume
23,014
EPS
0
Div Yield
0
P/E
-2
Market Cap
206,002,956
Related Instruments
AAVEUSD
2.476
(2.16%)
117.281 USD
L
LINK
-0.03000
(-0.73%)
4.10000 USD
L
LUNA
0.02000
(0.67%)
3.01000 USD
S
SOL
-0.07500
(-4.50%)
1.59000 USD
News

Title: Adaptimmune Therapeutics plc

Sector: Healthcare
Industry: Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.